- Home
- XGN vs ATRA Comparison
XGN vs ATRA Comparison
Compare XGN & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- ATRA
- Stock Information
- Founded
- XGN 2002
- ATRA 2012
- Country
- XGN United States
- ATRA United States
- Employees
- XGN N/A
- ATRA N/A
- Industry
- XGN Medical Specialities
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XGN Health Care
- ATRA Health Care
- Exchange
- XGN Nasdaq
- ATRA Nasdaq
- Market Cap
- XGN 49.4M
- ATRA 43.4M
- IPO Year
- XGN 2019
- ATRA 2014
- Fundamental
- Price
- XGN $2.83
- ATRA $9.05
- Analyst Decision
- XGN Buy
- ATRA Hold
- Analyst Count
- XGN 1
- ATRA 6
- Target Price
- XGN $7.00
- ATRA $24.88
- AVG Volume (30 Days)
- XGN 20.0K
- ATRA 86.9K
- Earning Date
- XGN 11-11-2024
- ATRA 10-30-2024
- Dividend Yield
- XGN N/A
- ATRA N/A
- EPS Growth
- XGN N/A
- ATRA N/A
- EPS
- XGN N/A
- ATRA N/A
- Revenue
- XGN $56,660,000.00
- ATRA $62,387,000.00
- Revenue This Year
- XGN $9.98
- ATRA $1,190.80
- Revenue Next Year
- XGN $13.63
- ATRA N/A
- P/E Ratio
- XGN N/A
- ATRA N/A
- Revenue Growth
- XGN 7.05
- ATRA 809.03
- 52 Week Low
- XGN $1.30
- ATRA $4.98
- 52 Week High
- XGN $3.71
- ATRA $39.50
- Technical
- Relative Strength Index (RSI)
- XGN 49.26
- ATRA 59.48
- Support Level
- XGN $2.64
- ATRA $8.68
- Resistance Level
- XGN $2.98
- ATRA $10.05
- Average True Range (ATR)
- XGN 0.16
- ATRA 0.52
- MACD
- XGN -0.00
- ATRA 0.17
- Stochastic Oscillator
- XGN 48.44
- ATRA 64.91
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).